Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Emergent BioSolutions excels in Q3, poised for growth opportunities

Emergent BioSolutions delivered a strong Q3 performance, showcasing financial resilience, operational excellence, and strategic advancements across key business segments.
While facing challenges in pricing dynamics and revenue mix, the company's focus on growth opportunities, compliance, and leadership appointments positions them for sustained success.
With a solid financial foundation, improved guidance, and a strategic roadmap for growth, Emergent is well-equipped to navigate challenges, capitalize on opportunities, and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Radnor, Pennsylvania--(Newsfile Corp. - April 27, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") investors that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline:...

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. - EBS

SAN FRANCISCO, April 27, 2021 /PRNewswire/ -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.  Class Period: July 6, 2020 - Mar. 31, 2021 Lead Plaintiff Deadline: June 18, 2021 Visit: www.hbsslaw.com/investor-fraud/EBS Contact an Attorney Now: EBS@hbsslaw.com                                              844-916-0895 Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action: ­Throughout the class period, Defendants touted Emergent's deals with J&J and AstraZeneca to produce their vaccine candidates and separate production contract with the U.S. government.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO's Insider Sales

NEW YORK--(BUSINESS WIRE)-- #EBS--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.'s Directors and Officers for Breach of Fiduciary Duties – EBS

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.'s Directors and Officers for Breach of Fiduciary Duties – EBS

The go-to government contractor is in deep trouble. Should investors buy the dip?

Is There Any Hope Left for Emergent BioSolutions?

Boston, Massachusetts--(Newsfile Corp. - April 26, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Emergent to submit their information. Investors may...

EBS INVESTOR ALERT: Class Action Lawsuit Filed

The CEO of the Baltimore lab that botched 15 million doses of the Johnson & Johnson vaccine last month sold more than $10 million worth of shares in his company before it disclosed the disastrous mistake.

Lab CEO sold $10 million in stock before news of J&J vaccine mishap

The CEO of Emergent BioSolutions, the government contractor that destroyed 15 million doses of Johnson & Johnson's COVID-19 vaccine, sold more than $10 million worth of his stock in the company before its share prices plummeted.

CEO of COVID-19 vaccine maker sold $10M in stock before company destroyed Johnson & Johnson doses

Emergent BioSciences' stock lost more than half of its value since the disclosure that it ruined as many as 15 million doses of Johnson & Johnson's Covid-19 vaccine at its Baltimore plant. But the company's CEO dumped more than $11 million worth of stock ahead of the stock's massive decline.

A vaccine maker ruined 15 million doses. Its CEO sold $11 million of stock before that was public

RADNOR, Pa., April 26, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021 , inclusive (the "Class Period").

Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.

LOS ANGELES--(BUSINESS WIRE)---- $EBS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Emergent investors have until June 18, 2021 to file a lead plaintiff motion. If you suffered a loss on your Emerg

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.

What's in Store for Emergent (EBS) This Earnings Season?

Emergent BioSolutions (EBS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Emergent BioSolutions (EBS)

NEW YORK, April 24, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.

EBS INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - EBS

Radnor, Pennsylvania--(Newsfile Corp. - April 24, 2021) -  The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the District of Maryland against Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent") on behalf of those who purchased or acquired Emergent common stock between July 6, 2020 and March 31, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who...

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. - EBS

SAN DIEGO & GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Emergent BioSolutions Inc (NYSE: EBS) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between July 6, 2020 and March 31, 2021. Emergent is a specialty biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases. If you suffered a loss due to Emer

SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders

BENSALEM, Pa.--(BUSINESS WIRE)---- $EBS #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) common stock between July 6, 2020 and March 31, 2021, inclusive (the “Class Period”). Emergent investors have until June 18, 2021 to file a lead plaintiff motion. Investors suffering losses on their Emergent investments are encouraged to contact the Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors

NEW YORK, April 23, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE: EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ebs.

EBS Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Emergent BioSolutions Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)---- $EBS #classaction--Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)

LOS ANGELES--(BUSINESS WIRE)---- $EBS #investors--The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?

Emergent Biosolutions (EBS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Emergent Biosolutions (EBS) is Poised to Beat Earnings Estimates Again

LOS ANGELES--(BUSINESS WIRE)---- $EBS #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Emergent investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securi

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors

An analyst lowered his price target on the stock.

Why Emergent BioSolutions Stock Is Falling Again Today

Emergent Biosolutions has been in the news lately but for the wrong reasons. Earlier this month, we advised caution on EBS stock when it was revealed that a “human error” in the company's plant resulted in the contamination of a batch of Johnson & Johnson's (NYSE: JNJ) Covid-19 vaccine.

Is The Worst Over For Emergent Biosolutions Stock?

BENSALEM, Pa.--(BUSINESS WIRE)---- $EBS #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) investors concerning the Company's possible violations of federal securities laws. On March 31, 2021, The New York Times published an article reporting that in late February 2021, employees at Emergent's Baltimore manufacturing plant “mixed up” ingredients of the different COVID-19 vaccines, contaminating up to 15 million dos

News for Emergent BioSolutions Stock (EBS)